The DTU is collaborating with the University of Cambridge on a new randomised control trial for people with cystic fibrosis related diabetes (CFRD). The trial has started to enroll participants with CFRD, a common comorbidity in cystic fibrosis (CF), affecting 15-20% of adolescents and 30-50% of adults. The recommended management is insulin therapy by multiple daily injections, which adds significantly to the burden of self-managing CF.
Closed-loop insulin delivery systems include an algorithm that responds to real-time glucose levels from a sensor continuously measuring interstitial glucose beneath the skin; the system then automatically adjusts insulin doses delivered through an insulin pump. CL4P-CF (Closed-Loop For People living with Cystic Fibrosis) is NIHR-funded, multi-centre, and 6 months long and aims to find out if a hybrid closed-loop system - compared with standard insulin treatment plus a glucose sensor - can improve control of blood glucose and quality of life in young people and adults with CFRD.